Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VADS Are Ready For Wider Population Trial After REMATCH, Experts Agree

This article was originally published in The Gray Sheet

Executive Summary

The high complication rate associated with Thoratec's HeartMate VE ventricular assist device (VAD) in the seminal REMATCH trial should not deter investigators from testing VADs as a destination therapy in patients less ill than the REMATCH cohort, panelists agreed at an April 10 symposium on trials of mechanical circulatory support in Washington, DC
Advertisement

Related Content

Thoratec HeartMate A Good Choice For The Very Sick Despite Risks – Panel
Thoratec HeartMate A Good Choice For The Very Sick Despite Risks – Panel
Advertisement
UsernamePublicRestriction

Register

MT016426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel